Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
The latest announcement is out from Rockwell Med ( (RMTI) ).
On May 20, 2025, Rockwell Medical, Inc. held its 2025 Annual Meeting of Stockholders, where several key proposals were voted on. The election of two Class I directors, approval of executive compensation, ratification of EisnerAmper LLP as the independent accounting firm, and an amendment to the 2018 Long Term Incentive Plan were all addressed, reflecting the company’s ongoing governance and strategic planning efforts.
The most recent analyst rating on (RMTI) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Rockwell Med stock, see the RMTI Stock Forecast page.
Spark’s Take on RMTI Stock
According to Spark, TipRanks’ AI Analyst, RMTI is a Neutral.
Rockwell Med’s overall stock score reflects a company navigating challenges and opportunities. Financial performance is stable but faces growth hurdles. Technical indicators suggest bearish sentiment, while valuation remains a concern with a negative P/E ratio. The earnings call offers mixed signals: positive diversification efforts but revenue decline and negative EBITDA pose risks.
To see Spark’s full report on RMTI stock, click here.
More about Rockwell Med
Rockwell Medical, Inc. operates in the healthcare industry, focusing on providing innovative products and services for patients with end-stage renal disease and chronic kidney disease.
Average Trading Volume: 262,080
Technical Sentiment Signal: Sell
Current Market Cap: $35.54M
See more insights into RMTI stock on TipRanks’ Stock Analysis page.